REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm
April 17, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Regeneron...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
April 11, 2024 13:15 ET
|
Schall Law
The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm
March 22, 2024 13:20 ET
|
KUEHN LAW, PLLC
Kuehn Law investigates potential breach of fiduciary duties by Regeneron Pharmaceuticals officers and directors. Shareholders urged to contact for details.
Regeneron Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
July 25, 2023 15:04 ET
|
Block & Leviton LLP
BOSTON, July 25, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) for potential securities law violations. Investors who have lost money...
REGN Shareholder News: Johnson Fistel Encourages Regeneron Pharmaceuticals Shareholders with Losses to Contact the Firm Regarding Investigation
June 30, 2023 14:49 ET
|
Johnson Fistel, LLP
SAN DIEGO, June 30, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the...
Dyadic’s C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal
June 28, 2021 08:30 ET
|
Dyadic International, Inc.
Dyadic’s C1-cell protein production platform selected as a fast response vaccine manufacturing model against zoonotic diseases.C1 -cell platform expressed SBV antigen exhibited efficacy, potency, and...
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
August 31, 2020 20:54 ET
|
Bragar Eagel & Squire
NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regeneron, Inc. (NASDAQ:...
SHAREHOLDER ALERT: Lowey Dannenberg Is Investigating Regeneron Pharmaceuticals, Inc. (REGN) for Potential Breaches of Fiduciary Duty by Its Board of Directors
August 20, 2020 12:37 ET
|
Lowey Dannenberg, P.C.
NEW YORK, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating a potential breach of fiduciary duty claim...
Scott+Scott Attorneys at Law LLP Investigates Regeneron Pharmaceuticals, Inc.’s Directors and Officers for Breach of Fiduciary Duty – REGN
July 01, 2020 11:27 ET
|
Scott+Scott Attorneys at Law LLP
NEW YORK, July 01, 2020 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, is investigating whether certain directors...
Earth Science Tech Announces the Development of 3 New Advanced Formulated Cannabis CBD Nutraceuticals and 2 Cannabis CBD-Based Pharmaceutical Drugs under its Cannabis CBD Patent, IP and Technology
December 20, 2016 07:45 ET
|
Earth Science Tech, Inc.
Ft. Lauderdale, Dec. 20, 2016 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company focused on Cannabis (industrial hemp) Cannabinoid...